Previous 10 | Next 10 |
2024-02-07 10:30:00 ET SAN DIEGO - February 7, 2024 (Investorideas.com Newswire) Aethlon Medical, Inc. (Nasdaq: AEMD), a medical therapeutic company focused on developing products to treat cancer and life threatening infectious diseases, today announced that it will issue financial results ...
Aethlon Medical to Release Fiscal Third Quarter Financial Results and Host Conference Call on February 14, 2024 PR Newswire SAN DIEGO , Feb. 7, 2024 /PRNewswire/ -- Aethlon Medical, Inc. (Nasdaq: AEMD), a medical therapeutic company focused on developing prod...
2023-12-04 09:10:00 ET December 4, 2023 - Investorideas.com ( https://www.investorideas.com ) a global investor news source covering biotech and medical technology stocks releases a research/media alert for investors following the sector, featuring medical therapeutic company, Aethlon M...
2023-11-14 22:01:06 ET Aethlon Medical, Inc. (AEMD) Q2 2024 Earnings Conference Call November 14, 2023, 04:30 PM ET Company Participants Michael Miller - Rx Communications, IR Jim Frakes - Interim CEO and CFO Steven LaRosa - CMO Guy Cipriani - COO Confe...
2023-11-14 16:25:24 ET More on Aethlon Medical Aethlon Medical Q3 2024 Earnings Preview Aethlon Medical Q2 2024 Earnings Preview Seeking Alpha’s Quant Rating on Aethlon Medical Historical earnings data for Aethlon Medical Financial information ...
Aethlon Medical Announces Fiscal Second Quarter Financial Results and Provides Corporate Update PR Newswire Conference Call to be Held Today at 4:30 p.m. ET SAN DIEGO , Nov. 14, 2023 /PRNewswire/ -- Aethlon Medical, Inc. (Nasdaq: AEMD), a medical ...
Laser Photonics Corporation (LASE) is expected to report for Q2 2024 QuickLogic Corporation (QUIK) is expected to report $0.08 for Q3 2023 Stryve Foods Inc. (SNAX) is expected to report $-1.65 for Q3 2023 Reata Pharmaceuticals Inc. (RETA) is expected to report $-2.15 for Q3 2023 V...
Aethlon Medical Inc. (AEMD) is expected to report $-1.35 for Q2 2024
2023-11-13 17:35:42 ET More on Aethlon Medical Aethlon Medical gets new chief head Aethlon cleared by Indian drug authority to conduct phase 1 trial of its Hemopurifier Seeking Alpha’s Quant Rating on Aethlon Medical Historical earnings data for Aethlo...
2023-11-13 08:49:04 ET More on Aethlon Medical Aethlon cleared by Indian drug authority to conduct phase 1 trial of its Hemopurifier Aethlon Medical to effect 1-for-10 reverse stock split to meet Nasdaq rules Seeking Alpha’s Quant Rating on Aethlon Medical ...
News, Short Squeeze, Breakout and More Instantly...
Aethlon Medical Will Perform Pre-Clinical Studies to Explore Potential Synergies With its First-in-Class Hemopurifier® Blood Filtration System...
2024-02-21 09:30:00 ET SAN DIEGO - February 21, 2024 (Investorideas.com Newswire) Aethlon Medical, Inc. ( Nasdaq: AEMD ), a medical therapeutic company focused on developing products to treat cancer and life-threatening infectious diseases, today announced that it entered into a Materia...
Aethlon Medical Enters Into Materials Transfer Agreement for Santersus AG's NucleoCapture and HemoNucleoCapture Devices PR Newswire Aethlon Medical Will Perform Pre-Clinical Studies to Explore Potential Synergies With its First-in-Class Hemopurifier ® Blood Filtration...